India · Delayed Price · Currency is INR Divi's Laboratories Earnings Call Transcripts
Fiscal Year 2026
-
Q4 and FY26 saw strong revenue and profit growth, stable generics volumes, and robust custom synthesis and peptide pipelines. Despite global supply chain disruptions and rising costs, production and supply reliability were maintained, with a double-digit revenue growth outlook for FY27.
-
Q3 FY26 saw strong revenue and profit growth, driven by custom synthesis and stable generics volumes, despite ongoing pricing pressures. Backward integration, capacity expansion, and a robust export mix supported performance, with major custom synthesis projects set for commercialization in late 2027.
-
Q2 FY2026 saw 17% YoY revenue growth, record custom synthesis revenue, and stable generics volumes despite pricing pressure. CapEx will exceed INR 2,000 crore for FY2026, with major investments in capacity and technology. Gross margin remains stable at ~60% as product mix shifts toward custom synthesis.
-
Q1 FY26 saw strong revenue and profit growth, driven by robust custom synthesis and operational resilience despite ongoing pricing pressures in generics. Major CapEx is underway, with new facilities and advanced capabilities positioning for future growth.
Fiscal Year 2025
-
FY 2025 delivered robust revenue and profit growth, driven by strong custom synthesis momentum, stable generics, and expanding peptide and contrast media businesses. Strategic investments in capacity, technology, and supply chain resilience position the company for continued double-digit growth, with new long-term contracts set to contribute from late 2026.
-
Q3 FY25 saw strong revenue and profit growth, driven by custom synthesis and generics, with exports at 87% of sales. Kakinada Unit Three's commissioning boosts capacity, while double-digit growth and stable margins are targeted amid easing logistics and price pressures.
-
Q2 FY25 saw strong revenue and profit growth, driven by custom synthesis demand and resilient generic volumes despite pricing pressure. Major investments in capacity and technology, including Unit 3 expansion and peptide synthesis, position the company for future growth.
-
Q1 FY25 revenue grew 18% YoY to INR 2,197 crores, with strong custom synthesis and stable generics performance. Expansion projects and peptide investments are progressing, while API pricing pressure persists but is expected to stabilize.